nach oben

Familial Cancer

Erschienen in:

18.01.2019 | Review

Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018)

verfasst von: Mijke Visser, Nienke van der Stoep, Nelleke Gruis

Erschienen in: Familial Cancer | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Excerpt

Over 200,000 melanoma cases are diagnosed each year worldwide, leading to 55,000 deaths [1], and in most countries the annual incidence of melanoma is still increasing. Once melanoma has metastasised, it rapidly becomes life-threatening [1], underlining the importance of earlier diagnosis and better prevention. Melanoma aetiology is complex and heterogeneous, and environmental/lifestyle, phenotypic and genetic susceptibility contribute to melanoma genesis in a multifactorial manner [2]. UV radiation is known to be a major environmental risk factor, with a direct mutagenic role in melanoma pathogenesis [2, 3]. Phenotypic risk factors include light pigmentation, tendency to sunburn, inability to tan, and a large number of melanocytic nevi [2, 4]. …

Schadendorf D, van Akkooi ACJ, Berking C et al (2018) Melanoma. Lancet (London, England) 392(10151):971–984. https://doi.org/10.1016/s0140-6736(18)31559-9 CrossRef

Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer (Oxford, England: 1990) 41(1):45–60. https://doi.org/10.1016/j.ejca.2004.10.016 CrossRef

Hodis E, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–263. https://doi.org/10.1016/j.cell.2012.06.024 CrossRefPubMedPubMedCentral

Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer (Oxford, England: 1990) 41(14):2040–2059. https://doi.org/10.1016/j.ejca.2005.03.034 CrossRef

Leachman SA, Carucci J, Kohlmann W et al (2009) Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 61(4):677.e1–677.e14 https://doi.org/10.1016/j.jaad.2009.03.016 CrossRef

Aoude LG, Wadt KA, Pritchard AL, Hayward NK (2015) Genetics of familial melanoma: 20 years after CDKN2A. Pigm Cell Melanoma Res 28(2):148–160. https://doi.org/10.1111/pcmr.12333 CrossRef

Read J, Wadt KA, Hayward NK (2016) Melanoma genetics. J Med Genet 53(1):1–14. https://doi.org/10.1136/jmedgenet-2015-103150 CrossRefPubMed

Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264(5157):436–440CrossRefPubMed

Zuo L, Weger J, Yang Q et al (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12(1):97–99. https://doi.org/10.1038/ng0196-97 CrossRefPubMed

10.

Puntervoll HE, Yang XR, Vetti HH et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50(4):264–270 https://doi.org/10.1136/jmedgenet-2012-101455 CrossRefPubMedPubMedCentral

11.

Goldstein AM, Chan M, Harland M et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818–9828. https://doi.org/10.1158/0008-5472.Can-06-0494 CrossRefPubMed

12.

de Snoo FA, Bishop DT, Bergman W et al (2008) Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14(21):7151–7157. https://doi.org/10.1158/1078-0432.Ccr-08-0403 CrossRefPubMed

13.

Potjer TP, Kranenburg HE, Bergman W et al (2015) Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant. Eur J Hum Genet EJHG 23(5):711–714. https://doi.org/10.1038/ejhg.2014.187 CrossRefPubMed

14.

Wiesner T, Obenauf AC, Murali R et al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018–1021. https://doi.org/10.1038/ng.910 CrossRefPubMedPubMedCentral

15.

Aoude LG, Wadt K, Bojesen A et al (2013) A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS ONE 8(8):e72144. https://doi.org/10.1371/journal.pone.0072144 CrossRefPubMedPubMedCentral

16.

Cheung M, Talarchek J, Schindeler K et al (2013) Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 206(5):206–210. https://doi.org/10.1016/j.cancergen.2013.05.018 CrossRefPubMed

17.

Lin M, Zhang L, Hildebrandt MAT, Huang M, Wu X, Ye Y (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8(43):74936–74946. https://doi.org/10.18632/oncotarget.20465 CrossRefPubMedPubMedCentral

18.

Bishop DT, Demenais F, Iles MM et al (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41(8):920–925. https://doi.org/10.1038/ng.411 CrossRefPubMedPubMedCentral

19.

Yokoyama S, Woods SL, Boyle GM et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99–103. https://doi.org/10.1038/nature10630 CrossRefPubMedPubMedCentral

20.

Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94–98. https://doi.org/10.1038/nature10539 CrossRefPubMed

21.

Barrett JH, Iles MM, Harland M et al (2011) Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 43(11):1108–1113. https://doi.org/10.1038/ng.959 CrossRefPubMedPubMedCentral

22.

Robles-Espinoza CD, Harland M, Ramsay AJ et al (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46(5):478–481. https://doi.org/10.1038/ng.2947 CrossRefPubMedPubMedCentral

23.

Aoude LG, Pritchard AL, Robles-Espinoza CD et al (2015) Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 107(2):408. https://doi.org/10.1093/jnci/dju408 CrossRef

24.

Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961. https://doi.org/10.1126/science.1230062 CrossRefPubMed

25.

Aoude LG, Heitzer E, Johansson P et al (2015) POLE mutations in families predisposed to cutaneous melanoma. Fam Cancer 14(4):621–628. https://doi.org/10.1007/s10689-015-9826-8 CrossRefPubMed

26.

Teerlink CC, Huff C, Stevens J et al (2018) A nonsynonymous variant in the GOLM1 gene in cutaneous malignant melanoma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djy058 CrossRefPubMedPubMedCentral

27.

Robles-Espinoza CD, Velasco-Herrera Mdel C, Hayward NK, Adams DJ (2015) Telomere-regulating genes and the telomere interactome in familial cancers. Mol Cancer Res MCR 13(2):211–222. https://doi.org/10.1158/1541-7786.Mcr-14-0305 CrossRefPubMed

28.

de Lange T (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19(18):2100–2110. https://doi.org/10.1101/gad.1346005 CrossRef

29.

Donizy P, Kaczorowski M, Biecek P, Halon A, Szkudlarek T, Matkowski R (2016) Golgi-related proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in cutaneous melanoma: patterns of expression and prognostic significance. Int J Mol Sci 17(10):1619. https://doi.org/10.3390/ijms17101619 CrossRefPubMedCentral

30.

Law MH, Bishop DT, Lee JE et al (2015) Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet 47(9):987–995. https://doi.org/10.1038/ng.3373 CrossRefPubMedPubMedCentral

31.

Maurano MT, Humbert R, Rynes E et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337(6099):1190–1195. https://doi.org/10.1126/science.1222794 CrossRefPubMedPubMedCentral

32.

Oldridge DA, Wood AC, Weichert-Leahey N et al (2015) Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 528(7582):418–421. https://doi.org/10.1038/nature15540 CrossRefPubMedPubMedCentral

33.

Wright JB, Brown SJ, Cole MD (2010) Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 30(6):1411–1420. https://doi.org/10.1128/mcb.01384-09 CrossRefPubMedPubMedCentral

34.

Hua JT, Ahmed M, Guo H et al (2018) Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell 174(3):564–575. https://doi.org/10.1016/j.cell.2018.06.014 CrossRefPubMed

35.

Vallarelli AF, Rachakonda PS, Andre J et al (2016) TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget 7(33):53127–53136. https://doi.org/10.18632/oncotarget.10634 CrossRefPubMedPubMedCentral

36.

Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S (2012) Genetic counseling in melanoma. Dermatol Ther 25(5):397–402. https://doi.org/10.1111/j.1529-8019.2012.01499.x CrossRefPubMedPubMedCentral

37.

Swetter SM, Tsao H, Bichakjian CK et al (2018) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.08.055 CrossRefPubMed

38.

Potjer TP, Bollen S, Grimbergen A et al (2018) Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. Int J Cancer. https://doi.org/10.1002/ijc.31984 CrossRef

39.

Helgadottir H, Ghiorzo P, van Doorn R et al (2018) Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. J Med Genet. https://doi.org/10.1136/jmedgenet-2018-105610 CrossRefPubMed

40.

Frebourg T (2014) The challenge for the next generation of medical geneticists. Hum Mutat 35(8):909–911. https://doi.org/10.1002/humu.22592 CrossRefPubMed

41.

Petersen BS, Fredrich B, Hoeppner MP, Ellinghaus D, Franke A (2017) Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 18(1):14. https://doi.org/10.1186/s12863-017-0479-5 CrossRefPubMedPubMedCentral

42.

Cust AE, Drummond M, Kanetsky PA et al (2018) Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies. J Invest Dermatol 138(12):2617–2624. https://doi.org/10.1016/j.jid.2018.05.023 CrossRefPubMedPubMedCentral

43.

Gu F, Chen TH, Pfeiffer RM et al (2018) Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet 27(23):4145–4156. https://doi.org/10.1093/hmg/ddy282 CrossRefPubMed

44.

Leachman SA, Lucero OM, Sampson JE et al (2017) Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 36(1):77–90. https://doi.org/10.1007/s10555-017-9661-5 CrossRefPubMedPubMedCentral

Titel: Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018)
verfasst von: Mijke Visser
Nienke van der Stoep
Nelleke Gruis
Publikationsdatum: 18.01.2019
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 2/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-00115-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018)

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Recent advances in Lynch syndrome

Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma

Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort

TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort

Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie